These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 8638994

  • 1. Duration of the survival benefit of zidovudine therapy in HIV infection.
    Moore RD, Keruly JC, Chaisson RE.
    Arch Intern Med; 1996 May 27; 156(10):1073-7. PubMed ID: 8638994
    [Abstract] [Full Text] [Related]

  • 2. The effects on survival of early treatment of human immunodeficiency virus infection.
    Graham NM, Zeger SL, Park LP, Vermund SH, Detels R, Rinaldo CR, Phair JP.
    N Engl J Med; 1992 Apr 16; 326(16):1037-42. PubMed ID: 1347907
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
    Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC, Becker SL, Hansen NI, Graham NM, CHORUS Program Team.
    J Clin Epidemiol; 2004 Jan 16; 57(1):89-97. PubMed ID: 15019015
    [Abstract] [Full Text] [Related]

  • 7. Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
    Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE.
    Arch Intern Med; 1994 Mar 14; 154(5):566-72. PubMed ID: 8122950
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.
    J Infect Dis; 2004 Sep 15; 190(6):1046-54. PubMed ID: 15319852
    [Abstract] [Full Text] [Related]

  • 10. Race, sex, drug use, and progression of human immunodeficiency virus disease.
    Chaisson RE, Keruly JC, Moore RD.
    N Engl J Med; 1995 Sep 21; 333(12):751-6. PubMed ID: 7643881
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J, Caelyx/Kaposi's Sarcoma Spanish Group.
    Clin Infect Dis; 2008 Aug 01; 47(3):410-7. PubMed ID: 18582203
    [Abstract] [Full Text] [Related]

  • 17. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.
    Clin Infect Dis; 2006 Jan 01; 42(1):136-44. PubMed ID: 16323104
    [Abstract] [Full Text] [Related]

  • 18. Retention in care: a challenge to survival with HIV infection.
    Giordano TP, Gifford AL, White AC, Suarez-Almazor ME, Rabeneck L, Hartman C, Backus LI, Mole LA, Morgan RO.
    Clin Infect Dis; 2007 Jun 01; 44(11):1493-9. PubMed ID: 17479948
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.